Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-17

FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)

View source ↗

Summary

The FDA approved a supplemental application from Amneal Pharmaceuticals LLC to market a generic version of Levetiracetam.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)